Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.

Intensive glucose control improves kidney outcomes in patients with type 2 diabetes.

The effect of intensive glucose control on major kidney outcomes in type 2 diabetes remains unclear. To study this, the ADVANCE trial randomly assigned 11,140 participants to an intensive glucose-lowering strategy (hemoglobin A1c target 6.5% or less) or standard glucose control. Treatment effects on...

Bibliografski detalji
Glavni autori:	Perkovic, V, Heerspink, H, Chalmers, J, Woodward, M, Jun, M, Li, Q, MacMahon, S, Cooper, M, Hamet, P, Marre, M, Mogensen, C, Poulter, N, Mancia, G, Cass, A, Patel, A, Zoungas, S
Format:	Journal article
Jezik:	English
Izdano:	2013

Slični predmeti

Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
od: Zoungas, S, i dr.
Izdano: (2009)

Intensive glucose lowering and the risk of vascular events and premature death in patients with decreased kidney function: the ADVANCE trial
od: Ohkuma, T, i dr.
Izdano: (2019)

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
od: Patel, A, i dr.
Izdano: (2008)

Estimating individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes
od: Woodward, M, i dr.
Izdano: (2016)

Lowering blood pressure reduces renal events in type 2 diabetes.
od: de Galan, B, i dr.
Izdano: (2009)

High prevalence of chronic kidney disease in Thailand
od: Perkovic, V, i dr.
Izdano: (2008)

Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds
od: Zoungas, S, i dr.
Izdano: (2012)

Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial
od: Ninomiya, T, i dr.
Izdano: (2008)

Changes in albuminuria and the risk of major clinical outcomes in diabetes: results from ADVANCE-ON
od: Jun, M, i dr.
Izdano: (2017)

Changes in albuminuria and the risk of major clinical outcomes in diabetes: Results From ADVANCE-ON.
od: Jun, M, i dr.
Izdano: (2017)

Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes
od: Mohammedi, K, i dr.
Izdano: (2017)

Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: The advance trial
od: Hata, J, i dr.
Izdano: (2013)

Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials.
od: Ninomiya, T, i dr.
Izdano: (2013)

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial.
od: Patel, A, i dr.
Izdano: (2007)

Acute increases in serum creatinine after starting angiotensin-converting enzyme inhibitor-based therapy and effects of its continuation on major clinical outcomes in type 2 diabetes mellitus: the ADVANCE trial
od: Ohkuma, T, i dr.
Izdano: (2018)

Response of 1,5‐anhydroglucitol level to intensive glucose‐ and blood‐pressure lowering interventions, and its associations with clinical outcomes in the ADVANCE trial
od: Selvin, E, i dr.
Izdano: (2019)

Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial.
od: Hata, J, i dr.
Izdano: (2013)

The relationship between plasma 8-OH-deoxyguanosine and cardiovascular disease and survival in type 2 diabetes: results from the ADVANCE study
od: Thomas, M, i dr.
Izdano: (2018)

Associations between body mass index and the risk of renal events in patients with type 2 diabetes
od: Mohammedi, K, i dr.
Izdano: (2018)

Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study
od: Mohammedi, K, i dr.
Izdano: (2016)

Absence of peripheral pulses and risk of major vascular outcomes in patients with type 2 diabetes
od: Mohammedi, K, i dr.
Izdano: (2016)

Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial
od: Glasziou, P, i dr.
Izdano: (2007)

Side-effects and tolerability of combination blood pressure lowering according to blood pressure levels – an analysis of the PROGRESS and ADVANCE trials
od: Atkins, A, i dr.
Izdano: (2017)

Visit-to-visit Variability of Systolic Blood Pressure Predicts Macrovascular and Microvascular Events in Patients with Type 2 Diabetes: the ADVANCE Trial
od: Hata, J, i dr.
Izdano: (2012)

Severe Hypoglycemia and Risks of Vascular Events and Death
od: Zoungas, S, i dr.
Izdano: (2010)

Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis
od: Lv, J, i dr.
Izdano: (2012)

Intensive glucose control and macrovascular outcomes in type 2 diabetes.
od: Turnbull, F, i dr.
Izdano: (2009)

The impact of level of education on vascular events and mortality in patients with type 2 Diabetes mellitus: results from the ADVANCE study
od: Blomster, J, i dr.
Izdano: (2017)

The effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
od: Zoungas, S, i dr.
Izdano: (2017)

Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial
od: van Steen, S, i dr.
Izdano: (2018)

Blood pressure variables and cardiovascular risk: new findings from ADVANCE.
od: Kengne, A, i dr.
Izdano: (2009)

Microvascular and macrovascular disease and risk for major peripheral arterial disease in patients with type 2 diabetes
od: Woodward, M, i dr.
Izdano: (2016)

Self‐rated health scores predict mortality among people with type 2 diabetes differently across three different country groupings: findings from the ADVANCE and ADVANCE‐ON trials
od: Hua, X, i dr.
Izdano: (2020)

Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials.
od: Turnbull, F, i dr.
Izdano: (2008)

Use of the waist‐to‐height ratio to predict cardiovascular risk in patients with diabetes: Results from the ADVANCE‐ON study
od: Rådholm, K, i dr.
Izdano: (2018)

The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials
od: Czernichow, S, i dr.
Izdano: (2011)

Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial
od: Welsh, P, i dr.
Izdano: (2018)

Cardiac stress and inflammatory markers as predictors of heart failure in patients with type 2 diabetes: the ADVANCE trial
od: Ohkuma, T, i dr.
Izdano: (2017)

Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial.
od: Berthet, K, i dr.
Izdano: (2004)

Renal end points in clinical trials of kidney disease
od: Weldegiorgis, M, i dr.
Izdano: (2015)